These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23542729)

  • 1. Liver X receptors: emerging therapeutic targets for Alzheimer's disease.
    Sodhi RK; Singh N
    Pharmacol Res; 2013 Jun; 72():45-51. PubMed ID: 23542729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid metabolism and neuroinflammation in Alzheimer's disease: a role for liver X receptors.
    Kang J; Rivest S
    Endocr Rev; 2012 Oct; 33(5):715-46. PubMed ID: 22766509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver X receptor activation attenuates inflammatory response and protects cholinergic neurons in APP/PS1 transgenic mice.
    Cui W; Sun Y; Wang Z; Xu C; Peng Y; Li R
    Neuroscience; 2012 May; 210():200-10. PubMed ID: 22425753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors.
    Zelcer N; Khanlou N; Clare R; Jiang Q; Reed-Geaghan EG; Landreth GE; Vinters HV; Tontonoz P
    Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10601-6. PubMed ID: 17563384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Liver X Receptor in AD Pathophysiology.
    Sandoval-Hernández AG; Buitrago L; Moreno H; Cardona-Gómez GP; Arboleda G
    PLoS One; 2015; 10(12):e0145467. PubMed ID: 26720273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxysterols, cholesterol homeostasis, and Alzheimer disease.
    Vaya J; Schipper HM
    J Neurochem; 2007 Sep; 102(6):1727-1737. PubMed ID: 17573819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver X receptor activation restores memory in aged AD mice without reducing amyloid.
    Vanmierlo T; Rutten K; Dederen J; Bloks VW; van Vark-van der Zee LC; Kuipers F; Kiliaan A; Blokland A; Sijbrands EJ; Steinbusch H; Prickaerts J; Lütjohann D; Mulder M
    Neurobiol Aging; 2011 Jul; 32(7):1262-72. PubMed ID: 19674815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinoids as potential targets for Alzheimer's disease.
    Sodhi RK; Singh N
    Pharmacol Biochem Behav; 2014 May; 120():117-23. PubMed ID: 24582848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset.
    Dionísio PA; Amaral JD; Ribeiro MF; Lo AC; D'Hooge R; Rodrigues CM
    Neurobiol Aging; 2015 Jan; 36(1):228-40. PubMed ID: 25443293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.
    Balducci C; Paladini A; Micotti E; Tolomeo D; La Vitola P; Grigoli E; Richardson JC; Forloni G
    J Alzheimers Dis; 2015; 46(2):471-82. PubMed ID: 25777514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease.
    Sodhi RK; Singh N; Jaggi AS
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Aug; 384(2):115-24. PubMed ID: 21607645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective liver X receptor modulators (SLiMs): what use in human health?
    Viennois E; Mouzat K; Dufour J; Morel L; Lobaccaro JM; Baron S
    Mol Cell Endocrinol; 2012 Apr; 351(2):129-41. PubMed ID: 21907760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease.
    Browne TC; McQuillan K; McManus RM; O'Reilly JA; Mills KH; Lynch MA
    J Immunol; 2013 Mar; 190(5):2241-51. PubMed ID: 23365075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
    Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
    Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geniposide attenuates insulin-deficiency-induced acceleration of β-amyloidosis in an APP/PS1 transgenic model of Alzheimer's disease.
    Zhang Y; Yin F; Liu J; Liu Z; Guo L; Xia Z; Zidichouski J
    Neurochem Int; 2015 Oct; 89():7-16. PubMed ID: 25882165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model.
    Durairajan SS; Liu LF; Lu JH; Chen LL; Yuan Q; Chung SK; Huang L; Li XS; Huang JD; Li M
    Neurobiol Aging; 2012 Dec; 33(12):2903-19. PubMed ID: 22459600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.
    Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ
    Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of Liver X Receptor β expression in primary rat neurons by antisense oligodeoxynucleotides decreases secreted amyloid β levels.
    Wang Q; Wang S; Shi Y; Yao M; Hou L; Jiang L
    Neurosci Lett; 2014 Feb; 561():146-50. PubMed ID: 24394905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E in Alzheimer's disease: an update.
    Yu JT; Tan L; Hardy J
    Annu Rev Neurosci; 2014; 37():79-100. PubMed ID: 24821312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.